Neuvivo, Inc.
StreetZero Signal 63
About Neuvivo, Inc.
Neuvivo is a late-clinical stage biopharmaceutical company developing new treatments for ALS and other neurodegenerative diseases. The company was formed by industry leaders and scientists with the goal of improving the prognosis for patients diagnosed with diseases for which there are few current treatment options. Neuvivo is headquartered in Palo Alto, California and operates as a privately held B2B biotechnology firm.
LATEST FUNDINGPrivate Placement
$1.4M
Announced 2026-11-13
TOTAL RAISED$11M
IN THE NEWS
- 🔗 Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS | Neuvivo
- 🔗 Neuvivo 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- 🔗 Neuvivo - Products, Competitors, Financials, Employees, Headquarters Locations
- 🔗 Neuvivo Stock Price, Funding, Valuation, Revenue & Financial Statements
- 🔗 Neuvivo
EMPLOYEES1-10
FOUNDED2020
HQPalo Alto, CA, United States
Industry
Pharmaceuticals
Tags
BiotechnologyPharmaceuticalsALSDrug Discovery
Key highlights
- Raised $11M Series A in June 2023 led by PrimeStreet Group.
- Developing late-clinical stage treatment for ALS.
- Founded in 2020 and headquartered in Palo Alto, CA.
- PrimeStreet Capital GP Virit Vichitvadakan joined the board.
- Total funding reported as $11M across multiple rounds.
Ask StreetZero about Neuvivo, Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account